Want free veterinary info & resources?
Join our Pack & keep up with ALL the best veterinary stuff in our weekly eNews
*Unsubscribe anytime!!
If you work in a veterinary practice or in the pet industry or in a business that supplies goods or services to the industry and you have something to say - why not become a 'Guest Blogger'?
For more information click here to read our: Guidelines for Guest Bloggers
On a mission to find a treatment for canine lymphoma, biotech company PharmAust is reminding dog owners to check their dogs this National Pet Cancer Awareness Month for any unusual lumps under their skin that may be signs of cancer.
Close to 50% of dogs over the age of 10 will develop cancer and approximately 1 in 4 dogs will at some stage in their life develop cancer, according to the Vet Cancer Society.
Lymphoma is a common and aggressive cancer diagnosed in dogs. Symptoms can include swellings (enlarged lymph nodes), lethargy, weight loss and loss of appetite.
“At the moment, there is no cure for B cell lymphoma. Studies show only 50% of dogs with B cell lymphoma will survive without treatment for around 30 days and the other half will mostly have severe progressive disease,” said veterinarian Dr Kim Agnew, who is the Principal Investigator of PharmAust’s anti-cancer drug trial for dogs with b cell lymphoma
“Currently, the best indicated treatment option for canine lymphoma is chemotherapy, which comes with its own set of logistical challenges regarding access to treatment and adverse events. However, 20% of dogs can be expected to live for 2 years, but unfortunately, relapse can occur within six to 12 months of treatment.
”Working towards an alternative successful treatment for canine lymphoma, PharmAust is continuing recruitment of pet dogs in Australia, New Zealand and the United States with untreated B cell lymphoma to finalise evaluation of a promising, newly formulated anti-cancer drug, Monepantel (MPL).
“MPL is already approved for veterinary use for a different indication and species, and PharmAust is aiming to repurpose MPL as a safe and effective cancer treatment,” said Dr Agnew.
PharmAust is encouraging dog owners to check their dogs for unusual lumps and bumps under the skin that may be a sign of cancer.
“This is something you should be doing on a regular basis,” said Dr Agnew. “The most noticeable symptom of lymphoma is swollen lymph nodes, which can be detected in several locations, including under the jaw, prescapular lymph nodes (when throat goes into the chest), under the armpits, inner thighs and right behind the knee.”
During Phase 2a and Phase 2b trials, Monepantel demonstrated effective anti-cancer activity and minimal side effects, which supports continued development into Phase 3 registration trials, said Dr Agnew.
“We want to provide a canine lymphoma treatment option that can be administered daily by the owner and allow the dog to maintain an excellent quality of life during treatment. Survival expectations are anticipated to align to a range of single active chemotherapy programs in dogs,” he said.
In Australia, participating veterinary trial centres have been set up in New South Wales, Queensland and Western Australia. For trial eligibility, participant case studies and veterinary trial centre locations, visit http://www.pharmaust.com/petdogtrial
Zoetis supporting the mental health of veterinarians, practice staff and nurses, as they work with their communities. Zoetis, the leading animal health business, has reached its goal of raising $100,000 for the Beyond Blue Support Service to support mental health...